Gestational Diabetes: Causes, Blood Sugar Targets, Treatment, and Long-Term Risk

What Is Gestational Diabetes and Why Does It Happen?

Gestational diabetes is a form of glucose intolerance that develops during pregnancy when placental hormones drive insulin resistance beyond what the maternal pancreas can compensate for. It is not the same as pregestational type 1 or type 2 diabetes, though all three share the common thread of elevated blood glucose.

During a healthy pregnancy, the placenta secretes human placental lactogen, progesterone, cortisol, and placental growth hormone. These hormones are necessary for fetal nutrition, but they progressively blunt insulin signaling in maternal muscle and fat tissue. A pancreas with adequate reserve simply ramps up insulin secretion. When reserve is limited, fasting and postprandial glucose rise to levels that meet diagnostic criteria for GDM.

Risk factors that reduce that reserve include pre-pregnancy overweight or obesity, a history of GDM in a prior pregnancy, a first-degree relative with type 2 diabetes, polycystic ovary syndrome (PCOS), and advancing maternal age. Non-Hispanic Black, Hispanic, Asian American, and American Indian women have higher rates than non-Hispanic white women, reflecting both genetic susceptibility and structural drivers of metabolic health. The CDC notes that GDM rates have risen in parallel with obesity prevalence over the past two decades.

Mechanistically, insulin resistance in GDM is not fundamentally different from the resistance seen in prediabetes or type 2 diabetes. The difference is timing and reversibility. Most women return to normal glucose tolerance within 12 weeks postpartum, but the underlying pancreatic beta-cell vulnerability persists, which explains the high lifetime conversion rate to type 2 diabetes discussed later.

How Is Gestational Diabetes Diagnosed?

The standard U.S. approach uses a two-step screening protocol at 24 to 28 weeks, though the one-step 75 g oral glucose tolerance test (OGTT) endorsed by the International Association of Diabetes and Pregnancy Study Groups (IADPSG) is an alternative some centers prefer.

Two-step approach:

Step 1 is a 50 g non-fasting glucose challenge test (GCT). A 1-hour plasma glucose at or above 130 to 140 mg/dL (threshold varies by center) triggers step 2.

Step 2 is a fasting 100 g, 3-hour OGTT. GDM is diagnosed when two or more values meet or exceed the Carpenter-Coustan thresholds: fasting 95 mg/dL, 1-hour 180 mg/dL, 2-hour 155 mg/dL, 3-hour 140 mg/dL. The American College of Obstetricians and Gynecologists (ACOG) endorses this two-step protocol as its preferred strategy.

One-step approach:

A fasting 75 g OGTT diagnoses GDM when any single value meets or exceeds: fasting 92 mg/dL, 1-hour 180 mg/dL, or 2-hour 153 mg/dL. This lower threshold captures more cases but also generates more diagnoses in women who might never experience adverse outcomes, so the debate over which protocol is superior remains active in obstetric literature. A 2021 Cochrane review (14 trials, N=3,854) found insufficient evidence to declare one screening strategy superior for maternal or infant outcomes.

Women with strong risk factors, including prior GDM, BMI above 35, or fasting glucose at the upper limit of normal on early prenatal labs, may be screened in the first trimester. A fasting plasma glucose of 92 to 125 mg/dL before 24 weeks now meets IADPSG criteria for GDM. Overt diabetes (fasting glucose at or above 126 mg/dL or HbA1c at or above 6.5%) found at any gestational age is classified as pregestational diabetes, not GDM, and requires more intensive management.

Blood Sugar Targets During a GDM Pregnancy

Tight glucose control directly reduces the risk of macrosomia, shoulder dystocia, neonatal hypoglycemia, and stillbirth. Targets are tighter than those used outside pregnancy because fetal glucose tracks maternal glucose continuously.

The ADA 2024 Standards of Medical Care in Diabetes recommend the following for women with GDM who are on glucose-lowering therapy:

• Fasting: <95 mg/dL
• 1-hour postprandial: <140 mg/dL
• 2-hour postprandial: <120 mg/dL

These targets are derived from the HAPO study (N=23,316), which showed a continuous relationship between maternal glucose at each OGTT threshold and adverse perinatal outcomes including birth weight above the 90th percentile, primary cesarean delivery, and neonatal hypoglycemia.

HbA1c is a less useful marker in GDM because the condition usually begins after the first trimester, red-cell turnover is faster in pregnancy, and a "normal" HbA1c can coexist with dangerous postprandial excursions. Continuous glucose monitoring (CGM) is an emerging adjunct. The CONCEPTT trial (N=325) showed that CGM in pregnant women with type 1 diabetes reduced the rate of large-for-gestational-age infants by 28% compared with self-monitoring alone, and interest in applying CGM to GDM is growing, though it is not yet standard of care for GDM specifically. CONCEPTT results are published in The Lancet.

Blood glucose logs remain the practical backbone of GDM monitoring. Most protocols ask for four readings per day: fasting and one or two hours after the start of each main meal.

Medical Nutrition Therapy: The First-Line Treatment

Diet is the starting point for every GDM diagnosis. Roughly 70 to 85% of women achieve target glucose levels through medical nutrition therapy (MNT) alone, without medication. The ADA recommends individualized MNT provided by a registered dietitian as the cornerstone of GDM management.

The core principles of MNT for GDM are carbohydrate control, distribution across three meals and two to three snacks, and avoidance of concentrated sweets. Total carbohydrate intake is typically set at 33 to 40% of total calories, with no single meal exceeding 30 to 45 g and breakfast often limited to 15 to 30 g because morning insulin resistance is most pronounced. A bedtime snack of 15 to 30 g carbohydrate with protein helps prevent fasting ketosis without spiking overnight glucose.

Specific foods that blunt postprandial glucose spikes include non-starchy vegetables, legumes, berries, whole grains, and dairy. Foods that reliably overshoot targets include fruit juice, white rice, white bread, sweetened yogurt, and tropical fruits eaten in large portions.

Physical activity after meals is an inexpensive adjunct that reduces 1-hour postprandial glucose by roughly 10 to 20 mg/dL in most women. A 15-minute walk after dinner is one of the most consistently effective non-pharmacologic tools available. A randomized trial published in Diabetes Care (N=84) showed that postmeal walking reduced 1-hour glucose by a mean of 18 mg/dL compared with pre-meal walking in women with GDM.

Weight gain targets during a GDM pregnancy follow the Institute of Medicine guidelines stratified by pre-pregnancy BMI. Women who begin pregnancy with obesity (BMI at or above 30) are advised to gain only 11, 20 pounds total, and some evidence supports that gestational weight gain below the IOM minimum in this group may improve perinatal outcomes without harm.

When Medication Is Needed: Insulin vs. Oral Agents

When two weeks of MNT fails to keep glucose within targets, pharmacotherapy is indicated. This applies to approximately 15 to 30% of women with GDM.

Insulin is the preferred agent. It does not cross the placenta in clinically meaningful amounts, has decades of safety data in pregnancy, and can be titrated with precision. The ADA and ACOG both list insulin as the preferred pharmacologic agent for GDM when lifestyle measures are insufficient.

A typical starting regimen targets the dominant glucose abnormality. Fasting hyperglycemia responds to intermediate-acting NPH at bedtime, starting at 0.2 units/kg. Postprandial spikes respond to rapid-acting insulin (aspart or lispro) dosed before the offending meal, starting at 1 unit per 10 to 15 g of carbohydrate. Insulin lispro (Humalog) and aspart (NovoLog) are FDA-approved for use in pregnancy; glargine (Lantus) is used off-label but a growing body of evidence suggests similar perinatal outcomes compared with NPH.

Dose adjustments typically occur every 3 to 7 days based on glucose logs, with increases of 10 to 20% per adjustment until targets are met. Women on insulin must monitor for hypoglycemia. Glucose below 70 mg/dL should be treated immediately with 15 g of fast-acting carbohydrate and rechecked in 15 minutes.

Metformin is the most studied oral alternative. The MiG trial (N=751) found that metformin was not inferior to insulin for the primary composite outcome of neonatal hypoglycemia, respiratory distress, phototherapy, birth trauma, 5-minute Apgar below 7, or preterm birth. However, 46.3% of women randomized to metformin required supplemental insulin to maintain targets. MiG trial results are available at NEJM. Metformin does cross the placenta; long-term offspring follow-up data show no cognitive or developmental harm through age 9, but studies beyond that age are limited.

Glyburide was once widely used but has fallen from favor. A 2015 meta-analysis found that glyburide was associated with higher rates of neonatal hypoglycemia and macrosomia compared with insulin, and ACOG no longer lists it as a preferred agent. That meta-analysis is indexed on PubMed.

GLP-1 receptor agonists and SGLT-2 inhibitors are contraindicated in pregnancy. Women who were using semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro) for type 2 diabetes or obesity management before pregnancy should discontinue these agents at least two months before planned conception or immediately upon discovering pregnancy, per FDA labeling and current ADA guidance.

Fetal and Neonatal Risks of Uncontrolled GDM

Poorly controlled GDM exposes the fetus to a persistently elevated glucose environment. The fetal pancreas responds by secreting excess insulin, driving accelerated growth. This produces macrosomia (birth weight above 4,000, 4 to 500 g), which in turn raises the risk of shoulder dystocia, brachial plexus injury, and operative delivery.

The HAPO study (N=23,316) quantified these associations precisely: for each standard deviation increase in fasting glucose, the odds of birth weight above the 90th percentile increased by 1.38-fold, primary cesarean by 1.11-fold, and clinical neonatal hypoglycemia by 1.08-fold.

Neonatal hypoglycemia occurs because the newborn's insulin secretion remains elevated after the high-glucose intrauterine environment disappears. Glucose checks in the first hours of life and early feeding are standard neonatal care after a GDM pregnancy.

Preeclampsia risk approximately doubles with GDM. Preterm birth rates are also higher, partly from indicated early delivery when fetal macrosomia or maternal complications are present. Stillbirth risk, while rare overall, is elevated when glucose control is poor in the third trimester, particularly in women with concurrent hypertension.

Long-Term Maternal Risk: From GDM to Type 2 Diabetes

A GDM diagnosis is one of the strongest known predictors of future type 2 diabetes. Women with GDM carry a 35 to 60% lifetime risk of developing type 2 diabetes, compared with roughly 7 to 10% in the general female population of similar age. A 2020 meta-analysis in JAMA Internal Medicine (20 cohort studies, N=1,332,373 women) found that GDM was associated with a relative risk of 9.51 for type 2 diabetes compared with normoglycemic pregnancies.

Risk conversion is not uniform. Women who were obese before pregnancy, needed insulin during pregnancy, or have a first-degree relative with type 2 diabetes convert at higher rates and more quickly, often within 5 to 10 years postpartum. Breastfeeding for at least 3 months reduces risk modestly, as does participation in a structured lifestyle intervention program.

The Diabetes Prevention Program (DPP, N=3,234) showed that intensive lifestyle intervention reduced progression from prediabetes to type 2 diabetes by 58% over 2.8 years, and a subgroup analysis confirmed similar benefits in women with prior GDM. DPP primary results are published at NEJM. Metformin 850 mg twice daily reduced progression by 31% in the same trial, a smaller but meaningful benefit for women who cannot sustain lifestyle changes alone.

Postpartum follow-up is not optional. ACOG and the ADA both recommend a 75 g OGTT at 4 to 12 weeks after delivery to rule out persistent diabetes or prediabetes. HbA1c alone misses cases in the early postpartum period. After that initial screen, women with a history of GDM should be retested every 1 to 3 years for the rest of their lives using fasting glucose, OGTT, or HbA1c.

Long-Term Offspring Risk

The intrauterine exposure to hyperglycemia programs metabolic changes in the child that persist well beyond delivery. Children born to women with GDM have higher rates of childhood obesity, impaired glucose tolerance, and type 2 diabetes in adolescence and young adulthood compared with children of normoglycemic pregnancies, even after adjusting for shared genetic risk.

A large Danish cohort study (N=1,074,437 offspring) published in Diabetologia found that children of mothers with GDM had a 7.76-fold higher risk of type 2 diabetes before age 22 compared with unexposed children. This risk persisted after sibling-pair analyses designed to separate intrauterine exposure from inherited susceptibility, suggesting the glucose environment itself, not genetics alone, drives part of this risk.

Breastfeeding offers some protection for the child as well. It is associated with lower rates of childhood overweight and improved insulin sensitivity in offspring, though the absolute effect size is modest.

Insulin Resistance, Prediabetes, and the GDM Spectrum

GDM sits on a continuum with prediabetes and type 2 diabetes. Many women diagnosed with GDM already had undetected prediabetes before conception; the metabolic stress of pregnancy simply made it visible.

Prediabetes is defined as fasting glucose 100 to 125 mg/dL, 2-hour OGTT glucose 140 to 199 mg/dL, or HbA1c 5.7 to 6.4%. The ADA estimates that 96 million U.S. adults, roughly 38% of the adult population, have prediabetes, and most are unaware of it. A postpartum OGTT showing 2-hour glucose of 140 to 199 mg/dL identifies prediabetes and should trigger immediate lifestyle counseling and annual monitoring.

Insulin resistance is the shared mechanism linking GDM, prediabetes, and type 2 diabetes. HOMA-IR (homeostatic model assessment of insulin resistance) scores above 2.5 in the postpartum period predict a higher rate of type 2 diabetes conversion. Some endocrinologists use postpartum HOMA-IR along with fasting glucose to risk-stratify women and decide how aggressively to pursue lifestyle intervention or metformin prophylaxis.

The HealthRX clinical team uses a three-tier postpartum risk framework for women with a history of GDM. Tier 1 (diet-controlled GDM, normal postpartum OGTT, BMI <27, no family history): annual fasting glucose and lifestyle counseling. Tier 2 (insulin-required GDM or prediabetes on postpartum OGTT): OGTT every 12 months, structured lifestyle program referral, and shared decision-making about metformin. Tier 3 (diabetes confirmed on postpartum OGTT or two or more high-risk features): immediate endocrinology referral and initiation of appropriate pharmacotherapy.

Managing GDM in Specific Populations

Women with type 1 diabetes who become pregnant require insulin throughout pregnancy and have different targets than GDM. Their fasting glucose target is <90 mg/dL and postprandial targets are tighter than for GDM. They benefit most from CGM, and the CONCEPTT data cited earlier were derived almost entirely from this population. CONCEPTT is indexed on PubMed.

Women with type 2 diabetes becoming pregnant should be transitioned from oral agents to insulin before conception when possible. Metformin may be continued in the first trimester while insulin is being established, but most agents including SGLT-2 inhibitors, GLP-1 agonists, DPP-4 inhibitors, and thiazolidinediones are stopped at or before conception.

Women with PCOS have a two- to three-fold higher baseline risk of GDM due to pre-existing insulin resistance. Metformin started before conception in women with PCOS may reduce GDM risk, though evidence from randomized trials is mixed. A 2020 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (9 trials, N=1,829) showed metformin reduced GDM incidence in PCOS pregnancies by 38%.

Adolescents with GDM are a small but growing group given rising rates of teen obesity. Insulin is strongly preferred over oral agents in this population given limited safety data.

Postpartum Care and Prevention of Type 2 Diabetes

The 4 to 12 week postpartum visit is arguably the most medically significant well-woman visit after a GDM pregnancy. It should include a 75 g two-hour OGTT (not just fasting glucose), a discussion of lifetime risk, breastfeeding support, and a plan for repeat testing.

Women whose glucose normalizes postpartum should not consider themselves "cured." Annual or biennial testing using fasting glucose, HbA1c, or a 2-hour OGTT is the standard recommended interval, with the shorter interval for women with additional risk factors. ACOG's postpartum guidance recommends the 75 g OGTT at 4 to 12 weeks and then screening every 1 to 3 years thereafter.

Lifestyle change remains the most effective prevention tool. Weight loss of 5 to 7% of body weight through calorie reduction and 150 minutes per week of moderate-intensity physical activity replicates the DPP protocol that cut type 2 diabetes incidence by 58%. Structured programs modeled on the DPP are available through the CDC-led National Diabetes Prevention Program (National DPP) and are covered by many insurers for women with a history of GDM. The CDC National DPP is described at the CDC diabetes site.

For women who meet criteria for prediabetes postpartum and cannot achieve sustained lifestyle change, metformin 850, 1 to 000 mg twice daily is a reasonable long-term option. It is safe during breastfeeding. The ADA recommends considering metformin for diabetes prevention specifically in women with a history of GDM who develop prediabetes. See ADA Standards of Care Section 3.

Women interested in future pregnancies should aim to reach a healthy weight before the next conception to reduce recurrence risk. GDM recurs in 30 to 84% of subsequent pregnancies depending on how much weight is retained between pregnancies.